The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Shares were issued in Oct 2020 , just took till now to get on companies house website.
No shares have been issued to anyone yet and they cannot yet be traded.
Eligibility to receive them was back then, and was based on ownership of TILS shares (1 for 1).
Stemprinter Sciences Limited was incorporated on 3 September 2020. The aquisition of that company was made by Accustem Sciences Limited on 30 October 2020.
All will become clear by the end of this month, I hope and will be worth the wait. With the right marketing and key deliverables set out in viable timescales, it could be a very welcome addition to share portfolios.
There's a spelling error in the fifteenth line LOL
Apparently £10 per share !!!
Is that a ramp ?!! Lol
Looks like they are catching up in the simple governance that they were so far behind on. The PSC for stemprinter has been updated to Accustem as well. Each time a company allots shares it has to complete an allotment form .. there is no link to any buyer or other reason for that.. they ha e to state that it was for Stemprinter transfer as they didn’t actually receive cash. Good to see they are completing this stuff now though. Hopefully means they are getting their ducks in a row?
Would actually like to see the company develop over the coming months and see where it goes.
I think a sale is on the horizon.
it a cannot be cheap or it gets taken out
Someone said £10 upthread.
I don't agree. I think it will be higher or lower than that.
My 10 quid could just as easy be 10p !! No one has any idea just now ( other than the BOD).
GK, as of yet, the only valuation we have for Accustem is the HC Wainwright valuation of $280 million.
https://www.proactiveinvestors.co.uk/companies/amp/news/929555
"No one has any idea just now ( other than the BOD)."
They don't know either
Surely they will have some idea.
IIRC in the TILS accounting It was valued at spin off time at £3m so that would make each share something under 2p wouldn't it? But that assumes they haven't spent any of the £1m cash and that the value of the transferred-out assets remains at £2m, whereas I recall it was thought on here that it would probably be worth considerably more.
Fwd sales (orders placed) need to be taken into account in the valuation - they've definitely had plenty of time to build those up! - as well as market cap of the product they are hoping to take market share from.
Just me hoping that they are manufacturing the drugs via a large British firm like GSK who not only have well established supply lines but are also aiming to split their business in two in 2022 with one focusing on Biopharma and the other on consumer health care? They could make a big splash with a buyout at that point
Hi Lurking,
Accustem is a prognostic tool, rather than drug. They've developed a multi-gene assay which is, in theory, more accurate than existing tools for assessing best treatment approach following breast cancer (specific types). Improved effectiveness of prognosis means treatment can be better targeted, but also probably a cost element for trusts to ensure investment is used appropriately.
In terms of valuation, very much an unknown. As someone mentioned previously, only figure we have is $280mn from HC. Wainwright but that was nothing more than 10% of what Exact sciences paid for Genomic Health 3 years ago.
I'm hoping when they launch, there'll be other positive news. CE marking was due in November so hoping that is done now, and they were also pushing for FDA approval in the US. That would help with momentum post-launch. Would then be interesting if they can state they've launched it in Italy, but may be a bit soon for that.
We know they'll need a fund raise given only $3mn (from memory) has come from TILS, but that's not a bad thing in my view.
Valuation I guess will be down to the usual market considerations, but key for me will be perceived performance (but CE marking / FDA should help with that), ease of replication of the efficacy for competition, and TCO for customers (cost vs benefit of using) to assess market uptake.
Just my thoughts...
Exact paid $2.8Billion ( albiet included 1000 staff which was arguably a negative ) and our tool is 40% to 50% superior, then if I was Exact a would not want a competitor with a superior product disrupting my market.
Only option open to them is to take it out, which then begs the question, at what price?
my answer is that it has to be in the billions purely based on the $2.8b they have paid and then take account of the year on year revenue which will take a dive and you can come up with some tasty figures.
I don't have enough beads on my abacus, some I'm sure someone can do the Math.
vbw